You are here

Epigen Biosciences, Inc.

Company Information
Address
10225 Barnes Canyon Road Suite A104
San Diego, CA 92121
United States


http://www.epigenbiosciences.com

Information

UEI: L1EDVCGK2327

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. New Therapy for the Treatment of Primary Biliary Cholangitis.

    Amount: $448,110.00

    Project Summary Primary biliary cholangitis (PBC) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and eventually destroyed. When bile ducts are depleted, th ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Candidate selection of a LPAR1 antagonist for therapeutic application in NASH

    Amount: $971,732.00

    Summary The ultimate goal of this application is to develop one of Epigen’s proprietary antagonists of the lysophosphatidic acid receptor 1 (LPAR1) for the effective treatment of liver fibrosis asso ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  3. Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy

    Amount: $2,026,502.00

    PROJECT SUMMARY Diabetic neuropathy (DPN) is a major unmet health concern where over half of the estimated 33 million people in the US with type 1 or type 2 diabetes will develop neuropathy1. There is ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  4. Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis

    Amount: $449,984.00

    Abstract The endoplasmic reticulum (ER) protein sigma-1 receptor represents a unique chaperone activity in the central nervous system, and it exerts a potent influence on several neurotransmitter syst ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  5. Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH

    Amount: $397,398.00

    Summary The ultimate goal of this application is to develop one of Epigen’s proprietary antagonists of the lysophosphatidic acid receptor 1 (LPAR1) for the effective treatment of liver fibrosis asso ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  6. Novel therapy for Fragile X syndrome

    Amount: $2,206,174.00

    PROJECT SUMMARY Fragile X syndrome (FXS) is the most common inheritable form of cognitive impairment and the leading known genetic cause of autism. FXS is caused by the loss of expression of the fragi ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  7. Novel agents for idiopathic pulmonary fibrosis

    Amount: $299,983.00

    SummaryThe ultimate goal of our project is to develop novel therapeutics effective in idiopathic pulmonary fibrosis, a chronic, progressive and fatal fibrotic lung disease, of unknown etiology. It occ ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  8. Assessment of a selective kinase inhibitor in pre-clinical models of NASH

    Amount: $375,033.00

    Summary The ultimate goal of this application is to develop one of Epigen’s proprietary, selective and drug-like kinase inhibitors for the effective treatment of liver fibrosis associated with chron ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  9. Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease

    Amount: $2,171,366.00

    Alzheimerandapos;s disease (AD) is a devastating disease, with an insidious onset and relentless progress. It produces distressing changes in memory, thought, perception, and often behavior. These cha ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  10. Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes

    Amount: $390,335.00

    PROJECT SUMMARY Analgesia for post operative populations remains a significant health need that calls for innovative therapies which improve both safety and outcome measuresRecent FDA drug safety warn ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government